On Sunday (31 Mar), the Straits Times published an article reporting on what some of the angry Hyflux investors told its reporters during the protest at Hong Lim Park, where at least 500 protesters had gathered on Sat (30 Mar). Many are looking at losing 80-97% of their life savings and retirement funds which they have invested heavily in Hyflux preference shares and perpetual securities (i.e, high-risk bonds).

One of the investors, Mdm B. Chua, 62, lost $6,000 while her husband $100,000 investing in Hyflux preference shares and perpetual securities. Mdm Chua said, “We invested in Hyflux because government support for the company was very strong. We invested because Temasek had invested. And Temasek must have done its due diligence.”

“When banks sold the securities to us, they told us ‘Temasek invested, so don’t worry. And if you don’t buy, somebody else will’,” Mdm Chua added. “Investors went in because it was a national asset.”

“Many of us had kept quiet initially. But I felt I had to come to the protest. We must voice that we do care,” she said. Indeed, many hold the same view as Mdm Chua.

Temasek: We exited Hyflux well before issuance of Hyflux preference shares and perpetual bonds

After the news was reported, Temasek immediately wrote a letter to ST Forum to clarify. The letter was published yesterday (‘Temasek and its unit have not had investments in Hyflux since 2006‘, 1 Apr).

Mr Stephen Forshaw, Head of Public Affairs from Temasek International, wrote to say that Temasek’s investment in Hyflux was “part of an initiative during the early 2000s to invest in Singapore small and medium-sized enterprises”. It was to “support their growth in promising sectors”, such as water technology, he said.

“Upon completion of its investment objectives, Temasek exited its Hyflux investment,” he clarified. “This was before 2006, as noted in the news article – well before the issuance of Hyflux preference shares in 2011 and their perpetual bonds in 2016.”

In other words, Temasek is saying that it had already got out of Hyflux before the issuance of Hyflux preference shares in 2011 and their perpetual bonds in 2016.

Mr Forshaw went on to explain that Temasek continues to invest in Singapore SMEs via an independently managed fund, Heliconia Capital Management.

“Guided by its own board and management, Heliconia seeks to invest growth capital in Singapore-based SMEs. In addition to risk capital, Heliconia management also works with its investee companies on strategies and opportunities for regional or international growth,” he said.

“Neither Temasek nor Heliconia has had any investments in Hyflux since 2006.”

Heliconia board director continues to sit on Hyflux board

According to the information on its website, Heliconia Capital Management is a “wholly owned subsidiary of Temasek Holdings”.

One of its board director is Gay Chee Cheong who still sits on the Board of Hyflux:

And indeed, on Hyflux website, it also confirmed that Gay Chee Cheong is indeed a board director of Hyflux. Not only that, he also heads the Board’s Remuneration Committee in Hyflux, which meant that he has an influence over Hyflux CEO Olivia Lum’s salary package. In addition, he is also a member of the Nominating, Audit and Investment Committees in Hyflux:

Gay Chee Cheong was awarded the Singapore Armed Forces (SAF) Overseas Training Award. He attended the Royal Military Academy (RMA) Sandhurst and the Royal Military College of Science, Shrivenham (UK). He was also previously with Singapore Technologies Pte Ltd as the General Manager/Director of a joint venture company. He appears to have risen to the rank of Lieutenant-Colonel while he was with the SAF.

So, while “neither Temasek nor Heliconia has had any investments in Hyflux since 2006”, Heliconia’s board director Gay Chee Cheong continues to sit on Hyflux’s board.

 

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

美国医护人员接种辉瑞疫苗 出现严重过敏反应

据《纽约时报》报导,美国阿拉斯加州有医疗前线人员,接种辉瑞(Pfizer)与BioNTech的冠病疫苗,10分钟后即出现严重过敏,脸部和身上出现皮疹、心跳加速和呼吸急促等症状。 《纽时》报导这名来自巴莱特(Bartlett)地区医院的医护人员,是在本周二(15日)接种,但10分钟后即出现过敏迹象。该医院急诊部主任Lindy Jones,则指出上述医护人员此前还接受了标准国民治疗,但症状反复,被送入加护病房观察。 原本打算让该医护人员在16日傍晚出院,不过仍决定让她继续留医。 还有第二名医护人员在周三注射疫苗,不过10分钟后也出现眼部浮肿、头晕和嗓子发痒症状。随即他被送入急救室注射肾上腺素和接受药物治疗,不过,院方解释这名人员并不是过敏,且一小时后可出院。 美国监管机构在发布紧急批准时,曾同时提醒民众,若对疫苗内成分有已知过敏反应者,应避免接种。 至于疫苗生产商辉瑞表示,尚未接到来自阿拉斯加严重过敏病例报告的细节,不过会积极与当地卫生机构合作以进行评估。 《纽约时报》指出,虽然辉瑞疫苗临床试验有4.4万人参与,有效率达到了95%,但阿拉斯加州出现的情况会加剧对疫苗副作用的担忧。 新加坡采购辉瑞疫苗 新加坡总理李显龙在本月14日傍晚,曾揭露政府拨款超过10亿元,以采购冠病19疫苗。所有公民和长期居住在本地的居民,都能免费接种冠病疫苗。 卫生科学局则批准辉瑞研发的冠病疫苗,预计月底就会抵达我国,相信将使我国成为全球率先获得疫苗的国家之一。 新加坡卫生部设立的冠病疫苗专家团早前称,辉瑞疫苗成效高达95%,其安全性与其他注册疫苗基本一致。…

President’s Address: Regurgitating only the existing priorities

President’s Address raises questions of why Parliament was prorogued in the first place.

不法之徒自称哥哥诱骗民众,陈佩玲发文澄清吁民众勿上当

麦波申区议员陈佩玲周六(20日)于脸书发文表示,有人自称是她的哥哥,诱骗民众加入一项中国投资方案。 陈佩玲于文内澄清,自己是独生女,并没有任何兄弟姐妹。她同时澄清,自己并没有参与任何一项投资方案,提醒民众不要因此上当。 陈佩玲接受《新明日报》时称,有网友与朋友前来询问投资计划,并告诉她有人自称是陈佩玲的哥哥,似乎想透过她来吸引民众投资,故他需要立即发文澄清,避免民众受骗,但目前并没有更多相关资料,无法得知他们的行动与地点。 至于是否会报警,陈佩玲说目前持观望态度,待掌握更多信息后才决定下一步怎么做。 利用部长或议员名义骗取民众信任 不法之徒的新招层出不穷,甚至利用部长或议员的名义,试图骗取民众的信任。近日来,许多部长如副总理王瑞杰与人力部张杨莉明。 今年5月网上流传关于副总理王瑞杰以600万元投资新公司的不实报道,王瑞杰随后亦脸书发文驳斥并提醒民众勿提供个人和信用卡号码和密码等财务资料;同样于今年5月,诈骗网站冒用人力部长杨莉明照片,误导用户并索取信用卡与银行信息,杨莉明亦在得知消息后脸书发文澄清。 除了利用我国政府的名义,骗徒近年来亦会冒充中国官员或公安的名义威胁民众。 根据警方日前所公布的数据显示,自1月至4月期间,已接获65类似的诈骗案件,大部分与冒称中国官方机关的身份进行诈骗,涉及了至少480万新元的损失,其中有4万8000新元的损失与比特币自动柜员机有关。 大部分受害者是华人。

Very important that civil society be strengthened: Ho Kwon Ping

“How important is freedom of press to economic future?” was the question…